IRIS
LAZZARIN, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.937
AS - Asia 4.678
NA - Nord America 4.259
SA - Sud America 1.080
AF - Africa 87
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 5
Totale 15.052
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.115
RU - Federazione Russa 2.803
CN - Cina 1.631
SG - Singapore 1.613
BR - Brasile 896
SE - Svezia 731
HK - Hong Kong 577
VN - Vietnam 434
IT - Italia 302
RO - Romania 269
FR - Francia 232
DE - Germania 202
GB - Regno Unito 110
IN - India 95
CA - Canada 76
AR - Argentina 75
FI - Finlandia 74
MX - Messico 50
BD - Bangladesh 48
TR - Turchia 41
ID - Indonesia 39
ZA - Sudafrica 39
PL - Polonia 37
IQ - Iraq 34
EC - Ecuador 33
NL - Olanda 32
AT - Austria 30
CO - Colombia 28
ES - Italia 27
JP - Giappone 25
IE - Irlanda 21
PK - Pakistan 19
LT - Lituania 15
PH - Filippine 15
UZ - Uzbekistan 15
UA - Ucraina 14
VE - Venezuela 14
AE - Emirati Arabi Uniti 13
MA - Marocco 13
SA - Arabia Saudita 12
CL - Cile 11
TN - Tunisia 11
BO - Bolivia 7
DZ - Algeria 7
LU - Lussemburgo 7
MD - Moldavia 7
MY - Malesia 7
NP - Nepal 7
PY - Paraguay 7
CZ - Repubblica Ceca 6
BE - Belgio 5
EG - Egitto 5
EU - Europa 5
IL - Israele 5
IR - Iran 5
KW - Kuwait 5
OM - Oman 5
AU - Australia 4
KE - Kenya 4
PE - Perù 4
TH - Thailandia 4
UY - Uruguay 4
AZ - Azerbaigian 3
CI - Costa d'Avorio 3
JO - Giordania 3
KG - Kirghizistan 3
KZ - Kazakistan 3
NI - Nicaragua 3
PA - Panama 3
QA - Qatar 3
AL - Albania 2
BB - Barbados 2
BG - Bulgaria 2
BS - Bahamas 2
DO - Repubblica Dominicana 2
GE - Georgia 2
HN - Honduras 2
KR - Corea 2
LB - Libano 2
PS - Palestinian Territory 2
AM - Armenia 1
BF - Burkina Faso 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BZ - Belize 1
CH - Svizzera 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GF - Guiana Francese 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
LR - Liberia 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
NC - Nuova Caledonia 1
Totale 15.045
Salva come PNG Salva come JPEG
Città #
Dallas 1.428
Singapore 669
Moscow 643
Hong Kong 571
San Jose 486
Ashburn 449
Shanghai 283
Hefei 232
Lawrence 219
Princeton 219
Lauterbourg 201
Beijing 184
New York 169
Ho Chi Minh City 158
Milan 112
São Paulo 97
Hanoi 96
Los Angeles 91
Nuremberg 57
Helsinki 53
Boardman 44
Munich 41
Orem 39
Warsaw 35
Santa Clara 34
Guangzhou 33
Chennai 29
Denver 28
Montreal 27
Rome 25
Tokyo 25
Mexico City 24
Pune 24
Johannesburg 23
Washington 23
Seattle 22
Brooklyn 21
Curitiba 21
Frankfurt am Main 21
Manchester 21
Atlanta 20
Da Nang 19
Belo Horizonte 17
London 17
Poplar 17
Rio de Janeiro 17
Ankara 16
Chicago 16
Dublin 16
Shenzhen 16
Haiphong 15
Stockholm 15
Tashkent 15
Turku 15
Amsterdam 14
Boston 14
Houston 14
Toronto 14
Vienna 14
Brasília 13
Campinas 13
Phoenix 13
The Dalles 12
Baghdad 11
Goiânia 11
Guayaquil 11
Hải Dương 11
Porto Alegre 11
Quito 11
Tianjin 11
Reston 10
Miami 9
Querétaro 9
Barnet 8
Bogotá 8
Buenos Aires 8
Cesano Boscone 8
Council Bluffs 8
Hangzhou 8
Istanbul 8
New Delhi 8
Salvador 8
Betim 7
Ha Long 7
Kassel 7
Quanzhou 7
Sorocaba 7
São José do Rio Preto 7
Cape Town 6
Charlotte 6
City of London 6
Columbus 6
Dhaka 6
Guarulhos 6
Nova Iguaçu 6
Vancouver 6
Vitória 6
Xi'an 6
Belém 5
Biên Hòa 5
Totale 7.618
Salva come PNG Salva come JPEG
Nome #
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients 1.359
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 181
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 168
Biobanking for COVID-19 research 144
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 143
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 143
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients 142
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 125
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 114
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 111
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 111
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area 111
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 109
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort 104
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 103
Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients with Advanced Liver Disease during Anti-HCV Treatment with Direct-Acting Antiviral Regimens Including Ribavirin 100
Bictegravir 100
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 100
HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts 99
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 99
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 97
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 95
A study of cellular immunity in newborns after prevention of respiratory distress syndrome (RDS). 93
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients 93
Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy: The D:A:D Study 93
ABC of AIDS: Treatment of infections and antiviral agents 90
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 88
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 88
Cerebrospinal fluid beta 2-microglobulin in AIDS related central nervous system involvement. 88
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study) 88
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 86
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 86
Experiences with immunomodulant agents in HIV infections 85
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 85
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 85
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 84
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients 82
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 81
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 80
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients 80
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 80
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial 78
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption 77
Immunological status in heroin addicts: effects of methadone maintenance treatment 76
Darunavir for the treatment of HIV infection 76
Analysis of impediments to the maintenance in care of people with HIV in Italy 76
Point-of-care testing for hepatitis C virus infection at an Italian dental clinic: portrait of the pilot study population 75
Western blot in treated people with HIV-1 chronic infection: frequency of negative HIV-1 pol genes 75
Hepatitis delta infection among persons living with HIV in Europe 75
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen 74
Changing clinical and laboratory characteristics of Progressive Multifocal Leukoencephalopathy: a retrospective national cohort study 72
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 72
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 72
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 72
Benefits of a 12 week physical activity programme on muscle and bone health in people living with HIV 71
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 71
HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe 71
Early diagnosis of HIV infection in infants 70
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman 68
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 68
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 67
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 67
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 67
Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. 67
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 67
Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy 66
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 66
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 66
Impact of HAART on liver histology of HIV/HCV coinfected patients 65
Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission 65
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium 64
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 64
Morphogenesis, evolution and prognostic significance of lymphatic tissue lesions in HIV infection 64
T-lymphocyte subsets and delayed type hypersensitivity as classification parameters for HIV infection among drug-addicts 64
Clinical and epidemiological aspects of the first 50 cases of AIDS in Milan 64
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 64
Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals 64
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents 64
Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015 63
Risk of HIV-related diseases in heterosexuals importing infection from Zaire 62
Therapeutic trials with HPA23, alpha-IFN and ribavirin in AIDS patients 62
Long-lasting CCR5 internalization by antibodies in a subset of long-term non progressors: a possible protective effect against disease progression 61
Immune recovery and T cell subset analysis during effective treatment with maraviroc 60
Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients 60
Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study 60
Cytomegalovirus infection of the central nervous system in patients with aids: Diagnosis by DNA amplification from cerebrospinal fluid 60
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 60
Point-of-care testing for hepatitis C virus infection at alternative and high-risk sites: An Italian pilot study in a dental clinic 60
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 60
Risk behaviour and HTLV-1 seropositivity in injecting drug users 59
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy 59
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 59
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. 58
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 58
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. 58
Long-term suppression of viral replication in HIV-related lymphoma survivors: a case-control study 58
Cytomegalovirus pneumonia in AIDS patients: value of cytomegalovirus culture from BAL fluid and correlation with lung disease 57
Milan as possible starting point of LAV/HTLV III epidemic among Italian drug addicts 57
Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection 57
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. 57
Totale 9.362
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.452
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.452
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 1 0
2021/2022145 0 0 0 77 6 8 8 13 10 7 3 13
2022/20231.203 483 292 102 7 10 125 33 85 48 1 11 6
2023/2024605 7 29 81 49 45 137 13 68 0 15 80 81
2024/20253.101 375 58 37 81 83 256 711 232 487 360 162 259
2025/20269.973 718 880 1.425 1.260 633 308 927 646 2.491 559 126 0
Totale 15.322